CTSO
Cytosorbents Corporation
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-50/100
Last price
3.86
▼ 0.10 (2.64%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.00
Prev close
3.96
Day high
4.00
Day low
3.86
Volume
1.64K
Market cap
$12.15M
P/E (TTM)
—
52W range
3.66 – 20.00
Day trading desk
Gap from prior close
+1.01%
Prior close 3.96
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
3.75%
3.86 – 4.00
Position in range
0%
Near session low
ATR (14D)
0.51
13.19% of price
Prior day high
4.29
PDH
Prior day low
3.89
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 12.27K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.14%
-2.6%
1M
-43.71%
-44.8%
3M
-48.18%
-51.2%
6M
-68.91%
-83.4%
YTD
-69.83%
-83.4%
1Y
-79.49%
-94.8%
3Y
-89.17%
-170.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CTSO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+4.10M
Net buying
Buy transactions
108
4.15M shares
Sell transactions
5
51.01K shares
Net transactions
+113
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
510.69K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | CHAN PHILLIP P Chief Executive Officer |
BUY | 3.77K | $22.64K | Direct |
| Sep 15, 26 | SOBEL ALAN D Director |
BUY | 2.50K | $15.25K | Direct |
| Sep 14, 26 | CAPPONI VINCENT J President |
BUY | 2.07K | $12.54K | Direct |
| Sep 4, 26 | CHAN PHILLIP P Chief Executive Officer |
BUY | 200.00K | $70.00K | Direct |
| Jun 15, 26 | MARIANI PETER J Chief Financial Officer |
BUY | 100.00K | $44.00K | Direct |
| Jun 15, 26 | CHAN PHILLIP P Chief Executive Officer |
BUY | 261.47K | $104.90K | Direct |
| Nov 18, 25 | CHAN PHILLIP P Chief Executive Officer |
STOCK | 100.00K | $64.00K | Direct |
| Aug 8, 25 | CAPPONI VINCENT J President |
— | 89.10K | — | Direct |
| Aug 8, 25 | MARIANI PETER J Chief Financial Officer |
— | 71.50K | — | Direct |
| Aug 8, 25 | CHAN PHILLIP P Chief Executive Officer |
— | 105.60K | — | Direct |
| Aug 8, 25 | DELIARGYRIS EFTHYMIOS Officer |
— | 70.00K | — | Direct |
| Feb 24, 25 | CAPPONI VINCENT J President |
CONVERSION | 12.00K | $13.56K | Direct |
| Feb 24, 25 | MARIANI PETER J Chief Financial Officer |
CONVERSION | 32.63K | $36.87K | Direct |
| Feb 24, 25 | CHAN PHILLIP P Chief Executive Officer |
CONVERSION | 34.17K | $38.61K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BATOR MICHAEL G. |
Director | 151.27K | Conversion of Exercise of derivative security |
CAPPONI VINCENT J |
President | 40.39K | Purchase |
CHAN PHILLIP P |
Chief Executive Officer | 101.00K | Purchase |
DELIARGYRIS EFTHYMIOS |
Officer | 473.02K | Stock Award(Grant) |
MARIANI PETER J |
Chief Financial Officer | 638.11K | Purchase |
SOBEL ALAN D |
Director | 9.89K | Purchase |
Fundamentals
Market cap$12.15M
Enterprise value$37.46M
Revenue (TTM)$37.22M
Gross profit$26.65M
EBITDA$-10.35M
Net income$-18.21M
EPS (TTM)$-5.80
Free cash flow$-3.51M
Total cash$4.41M
Total debt$29.43M
Book value / share$-0.24
Shares outstanding3.15M
Float2.68M
Short % of float4.15%
Dividend yield0.00%
Beta (5Y)1.37
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue1.01
EV / EBITDA-3.62
Gross margin71.61%
Operating margin-24.58%
Profit margin-48.94%
Return on equity-336.21%
Return on assets-17.12%
Debt / equity—
Current ratio0.66
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $37.06M | $35.59M | $31.08M | $29.36M | +4.1% |
| Operating revenue | $37.06M | $35.59M | $31.08M | $29.36M | +4.1% |
| Cost of revenue | $10.57M | $10.71M | $9.13M | $13.96M | -1.3% |
| Gross profit | $26.49M | $24.89M | $21.95M | $15.40M | +6.4% |
| Research & development | $5.08M | $7.61M | $15.59M | $15.12M | -33.2% |
| Selling, general & admin | $35.65M | $33.73M | $38.31M | $37.14M | +5.7% |
| Total operating expense | $40.73M | $41.34M | $53.90M | $46.93M | -1.5% |
| Operating income | -$14.24M | -$16.45M | -$31.95M | -$31.52M | +13.5% |
| Net interest income | -$2.61M | -$1.40M | -$157.89K | $132.60K | -86.7% |
| Pre-tax income | -$8.60M | -$22.41M | -$30.06M | -$33.91M | +61.6% |
| Tax provision | -$401.00K | -$1.69M | -$813.74K | -$1.09M | +76.3% |
| Net income | -$8.20M | -$20.72M | -$29.25M | -$32.81M | +60.4% |
| Net income to common | -$8.20M | -$20.72M | -$29.25M | -$32.81M | +60.4% |
| Basic EPS | -2.60 | -7.60 | -13.00 | -14.93 | +65.8% |
| Diluted EPS | -2.60 | -7.60 | -13.00 | -14.93 | +65.8% |
| EBIT | -$5.99M | -$21.01M | -$29.90M | -$31.52M | +71.5% |
| EBITDA | -$4.36M | -$19.27M | -$27.88M | -$30.39M | +77.4% |
| Basic shares | 3.11M | 2.72M | 2.23M | 2.19M | +14.3% |
| Diluted shares | 3.11M | 2.72M | 2.23M | 2.19M | +14.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $6.25M | $3.28M | $14.13M | $22.14M | +90.5% |
| Cash & short-term investments | $6.25M | $3.28M | $14.13M | $22.14M | +90.5% |
| Accounts receivable | $7.55M | $7.32M | $6.06M | $5.66M | +3.1% |
| Inventory | $5.28M | $2.73M | $3.38M | $3.46M | +93.2% |
| Total current assets | $20.63M | $21.60M | $25.40M | $33.76M | -4.5% |
| Property, plant & equipment | $18.75M | $20.51M | $22.12M | $23.35M | -8.6% |
| Goodwill & intangibles | $3.23M | $3.72M | $3.91M | $4.39M | -13.3% |
| Total assets | $44.18M | $47.37M | $52.96M | $63.23M | -6.7% |
| Total current liabilities | $9.71M | $9.82M | $14.04M | $9.71M | -1.2% |
| Current debt | — | — | $2.50M | — | — |
| Long-term debt | $16.67M | $14.00M | $2.54M | $5.00M | +19.1% |
| Total debt | $29.11M | $26.89M | $18.31M | $18.25M | +8.2% |
| Total liabilities | $38.28M | $36.27M | $29.48M | $27.86M | +5.6% |
| Retained earnings | -$312.21M | -$304.01M | -$283.29M | -$254.00M | -2.7% |
| Shareholder equity | $5.90M | $11.11M | $23.48M | $35.37M | -46.9% |
| Working capital | $10.93M | $11.78M | $11.36M | $24.05M | -7.3% |
| Net tangible assets | $2.68M | $7.39M | $19.57M | $30.98M | -63.8% |
| Shares issued | 3.14M | 2.76M | 2.73M | 2.19M | +14.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$8.20M | -$20.72M | -$29.25M | -$32.81M | — | +60.4% |
| Depreciation & amortisation | $1.63M | $1.74M | $2.02M | $1.13M | — | -6.5% |
| Stock-based compensation | $2.77M | $3.76M | $4.16M | $3.80M | — | -26.5% |
| Change in working capital | -$1.03M | -$4.38M | $2.65M | -$3.56M | — | +76.5% |
| Operating cash flow | -$12.38M | -$14.43M | -$21.66M | -$28.23M | — | +14.2% |
| Capital expenditure | -$491.00K | -$669.00K | -$936.24K | -$6.46M | — | +26.6% |
| Investing cash flow | -$415.00K | -$669.00K | -$936.24K | -$6.46M | — | +38.0% |
| Share buybacks | — | — | — | -$40.36K | -$90.00K | — |
| Financing cash flow | $9.31M | $9.33M | $14.47M | $4.96M | — | -0.2% |
| Free cash flow | -$12.87M | -$15.10M | -$22.59M | -$34.69M | — | +14.8% |
| End cash position | $7.77M | $9.76M | $15.62M | $23.83M | — | -20.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $9.63M | $8.86M | $9.23M | $9.48M | $9.62M | — | +8.7% |
| Operating revenue | $9.63M | $8.86M | $9.23M | $9.48M | $9.62M | — | +8.7% |
| Cost of revenue | $2.58M | $2.73M | $2.43M | $2.82M | $2.80M | — | -5.5% |
| Gross profit | $7.05M | $6.13M | $6.80M | $6.67M | $6.81M | — | +15.0% |
| Research & development | $1.45M | $1.02M | $1.24M | $918.00K | $1.26M | — | +41.8% |
| Selling, general & admin | $7.96M | $8.15M | $9.44M | $8.61M | $9.17M | — | -2.3% |
| Total operating expense | $9.42M | $9.17M | $10.68M | $9.53M | $10.43M | — | +2.6% |
| Operating income | -$2.37M | -$3.04M | -$3.88M | -$2.86M | -$3.62M | — | +22.2% |
| Net interest income | -$868.00K | -$857.00K | -$746.00K | -$645.00K | -$616.00K | — | -1.3% |
| Pre-tax income | -$4.42M | -$5.13M | -$5.50M | -$3.57M | $1.95M | — | +13.9% |
| Tax provision | — | — | $0 | -$401.00K | — | $0 | — |
| Net income | -$4.42M | -$5.13M | -$5.50M | -$3.17M | $1.95M | — | +13.9% |
| Net income to common | -$4.42M | -$5.13M | -$5.50M | -$3.17M | $1.95M | — | +13.9% |
| Basic EPS | -1.40 | -1.60 | -1.80 | -1.00 | 0.60 | — | +12.5% |
| Diluted EPS | -1.40 | -1.60 | -1.80 | -1.00 | 0.60 | — | +12.5% |
| EBIT | -$3.55M | -$4.27M | -$4.75M | -$2.93M | $2.56M | — | +16.9% |
| EBITDA | -$3.17M | -$3.90M | -$4.37M | -$2.52M | $3.00M | — | +18.6% |
| Basic shares | 3.14M | 3.14M | 3.14M | 3.14M | 3.13M | — | +0.1% |
| Diluted shares | 3.14M | 3.14M | 3.14M | 3.14M | 3.36M | — | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.41M | $4.81M | $6.25M | $7.54M | $10.20M | -8.3% |
| Cash & short-term investments | $4.41M | $4.81M | $6.25M | $7.54M | $10.20M | -8.3% |
| Accounts receivable | $6.79M | $7.15M | $7.55M | $7.43M | $7.74M | -5.1% |
| Inventory | $3.69M | $4.48M | $5.28M | $4.00M | $3.71M | -17.7% |
| Total current assets | $15.74M | $17.76M | $20.63M | $21.31M | $22.99M | -11.4% |
| Property, plant & equipment | $17.78M | $18.28M | $18.75M | $19.27M | $19.69M | -2.7% |
| Goodwill & intangibles | $2.86M | $2.95M | $3.23M | $3.59M | $3.74M | -3.0% |
| Total assets | $37.96M | $40.56M | $44.18M | $45.75M | $47.99M | -6.4% |
| Total current liabilities | $24.02M | $16.30M | $9.71M | $10.11M | $9.84M | +47.4% |
| Current debt | $14.15M | $6.65M | — | — | — | +112.9% |
| Long-term debt | $3.09M | $10.31M | $16.67M | $14.57M | $14.38M | -70.0% |
| Total debt | $29.43M | $29.28M | $29.11M | $27.14M | $27.06M | +0.5% |
| Total liabilities | $38.71M | $38.37M | $38.28M | $36.73M | $36.40M | +0.9% |
| Retained earnings | -$321.75M | -$317.34M | -$312.21M | -$306.71M | -$303.54M | -1.4% |
| Shareholder equity | -$751.00K | $2.19M | $5.90M | $9.02M | $11.59M | -134.2% |
| Working capital | -$8.29M | $1.45M | $10.93M | $11.20M | $13.14M | -669.9% |
| Net tangible assets | -$3.62M | -$758.00K | $2.68M | $5.43M | $7.85M | -376.9% |
| Shares issued | 3.14M | 3.14M | 3.14M | 3.14M | 3.13M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$4.42M | -$5.13M | -$5.50M | -$3.17M | $1.95M | — | +13.9% |
| Depreciation & amortisation | $376.00K | $376.00K | $385.00K | $401.00K | $440.00K | — | 0.0% |
| Stock-based compensation | $368.00K | $544.00K | $886.00K | $488.00K | $573.00K | — | -32.4% |
| Change in working capital | $1.59M | $1.25M | -$1.17M | -$734.00K | $1.26M | — | +26.9% |
| Operating cash flow | -$583.00K | -$1.16M | -$4.83M | -$2.58M | -$1.51M | — | +49.8% |
| Capital expenditure | -$52.00K | -$72.00K | -$367.00K | — | -$132.00K | -$47.00K | +27.8% |
| Investing cash flow | $7.00K | -$46.00K | -$291.00K | $55.00K | -$132.00K | — | +115.2% |
| Financing cash flow | $0 | $0 | $2.48M | $0 | $0 | — | — |
| Free cash flow | -$635.00K | -$1.23M | -$5.19M | -$2.52M | -$1.64M | — | +48.5% |
| End cash position | $5.93M | $6.33M | $7.77M | $9.06M | $11.73M | — | -6.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
7.50
+94.5% from spot
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
7.50
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.90 | -1.40 | -55.6% |
| Mar 2026 | -1.10 | -1.60 | -45.5% |
| Dec 2025 | -1.00 | -1.80 | -80.0% |
| Sep 2025 | -0.93 | -1.00 | -7.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.90 | 2 | $9.91M | +4.5% |
| Next quarter | -0.70 | 2 | $10.46M | +13.3% |
| Current year | -4.40 | 2 | $38.88M | +4.9% |
| Next year | 0.00 | 1 | $44.16M | +13.6% |
Analyst targets & ownership
Mean target$47.50
High target$80.00
Low target$15.00
Implied upside1131.97%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 0
Hold1
Sell / Strong sell0 / 0
Held by insiders16.25%
Held by institutions25.53%
Institutions holding55
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.06
-5.07% from price
SMA 20
4.93
-21.72% from price
SMA 50
6.28
-38.57% from price
SMA 100
7.38
-47.76% from price
SMA 200
10.27
-62.47% from price
EMA 12
4.35
-11.45% from price
EMA 26
5.11
-24.59% from price
EMA 50
6.01
-35.83% from price
RSI (14)
25.4
Oversold
MACD (12,26,9)
-0.76
Hist -0.04
ATR (14)
0.51
13.19% of price
Realised vol 30D
77.7%
Annualised
Bollinger upper
6.78
20, 2σ
Bollinger lower
3.07
20, 2σ
50 / 200 cross
Death
6.28 vs 10.27
Trend bias
Below 200
-62.47%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.18
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
77.7%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-80.2%
Peak to trough
Max drawdown 5Y
-97.3%
Peak to trough
ATR 14
0.51
13.19% of price
Beta (reported)
1.37
5Y monthly, from filing
Short interest
Shares short
120.61K
Prior 107.90K
Change vs prior
+11.8%
Shorts adding
% of float
4.15%
Normal
% of shares out
3.83%
Against total outstanding
Days to cover
4.8
Liquid
Float
2.68M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 26, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jan 12, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Dec 16, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 14, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Nov 14, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Sep 16, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 20, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Aug 8, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jul 21, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jun 25, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| May 15, 25 | D. Boral Capital | MAINTAINED | Buy | Buy |
| May 15, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:20
Split dateSep 8, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-23
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-06
Corporate Changes & Voting Matters
8-K · 2026-06-25
Proxy Statements
PRE 14A · 2026-06-11
Headlines
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
PR Newswire · 7d ago
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR Newswire · 14d ago
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire · 27d ago
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
TMX Newsfile · 33d ago
CytoSorbents Announces Reverse Stock Split
PR Newswire · 34d ago
CTSO: CytoSorbents Announces Very Positive New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor
Zacks Small Cap Research · 34d ago
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
PR Newswire · 35d ago
CTSO: CytoSorbents Future Value Drivers Support Price Target of $4.00
Zacks Small Cap Research · 51d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.